Flexion Therapeutics, Inc. (NASDAQ:FLXN) had its price target increased by Janney Montgomery Scott to $570.00 in a report issued on Tuesday, The Fly reports. Janney Montgomery Scott currently has a fair value rating on the specialty pharmaceutical company’s stock.
A number of other research firms have also weighed in on FLXN. Wells Fargo & Company set a $39.00 price objective on shares of Flexion Therapeutics and gave the stock a buy rating in a research note on Friday, October 6th. BMO Capital Markets reaffirmed an outperform rating and issued a $37.00 price objective (up from $35.00) on shares of Flexion Therapeutics in a research note on Monday. Needham & Company LLC upped their price objective on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research note on Monday. Northland Securities reaffirmed a buy rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Wednesday, October 4th. Finally, Zacks Investment Research raised shares of Flexion Therapeutics from a sell rating to a hold rating in a research note on Monday, August 28th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $88.50.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11).
TRADEMARK VIOLATION WARNING: “Janney Montgomery Scott Boosts Flexion Therapeutics, Inc. (FLXN) Price Target to $570.00” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://sportsperspectives.com/2017/10/13/janney-montgomery-scott-boosts-flexion-therapeutics-inc-flxn-price-target-to-570-00.html.
In other news, insider Yamo Deniz bought 3,000 shares of Flexion Therapeutics stock in a transaction on Friday, September 1st. The stock was acquired at an average cost of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 5,375 shares of company stock valued at $131,575 over the last quarter. 15.98% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Fiduciary Trust Co. bought a new position in Flexion Therapeutics in the second quarter worth about $101,000. IFP Advisors Inc raised its holdings in Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. raised its holdings in Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares in the last quarter. Voya Investment Management LLC raised its holdings in Flexion Therapeutics by 25.8% in the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after purchasing an additional 2,651 shares in the last quarter. Finally, BB&T Securities LLC bought a new position in Flexion Therapeutics in the second quarter worth about $289,000. Institutional investors and hedge funds own 83.26% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.